Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a late-stage, clinical biopharmaceutical company centered on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The GOSS news feed on Stock Titan brings together company announcements, scientific updates, financial disclosures, and corporate developments that shape the investment and clinical narrative around its pulmonary hypertension programs.
News items for Gossamer Bio frequently cover progress in its registrational Phase 3 trials, including the PROSERA Study in PAH and the SERANATA Study in PH‑ILD. Investors and observers can follow updates on enrollment milestones, planned timelines for topline data, and key clinical endpoints such as six‑minute walk distance (6MWD), time to clinical worsening, and lung function measures. Scientific conference coverage, such as presentations at the European Respiratory Society (ERS) Congress, provides additional context on seralutinib’s mechanistic and translational data.
The GOSS news stream also reflects Gossamer Bio’s broader corporate and pipeline activities. This includes quarterly financial results and business updates, collaboration news with the Chiesi Group, stockholder meeting outcomes, and announcements related to its option agreement to acquire Respira Therapeutics and the investigational inhaled vardenafil candidate RT234. Regular disclosures of employment inducement stock option grants highlight hiring and equity compensation practices under Nasdaq Listing Rule 5635(c)(4).
By monitoring Gossamer Bio news on Stock Titan, readers can track how clinical data, regulatory milestones, scientific presentations, financial performance, and strategic transactions interact within the company’s focused pulmonary hypertension strategy. This page is intended as a central hub for GOSS-related headlines and press releases, helping users follow the evolution of its late-stage programs over time.
Gossamer Bio (NASDAQ:GOSS) has announced five scientific presentations featuring seralutinib at the upcoming European Respiratory Society (ERS) Congress 2025 in Amsterdam. The presentations include one oral and four poster sessions highlighting seralutinib's potential in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The presentations will showcase various aspects of seralutinib's therapeutic potential, including its effects on fibrotic pathways, vascular inflammation reduction, anti-fibrotic effects in patient-derived models, impact on pulmonary artery vessel volume, and its role in decreasing endotrophin production. The drug is being jointly developed by Gossamer Bio and the Chiesi Group under a global collaboration agreement.
Gossamer Bio (Nasdaq: GOSS), a late-stage clinical biopharmaceutical company, announced the approval of inducement grants to two non-executive employees. The grants consist of non-qualified stock options to purchase up to 87,500 shares of common stock under the company's 2023 Inducement Plan.
The options have an exercise price of $2.94 per share, matching GOSS's closing price on September 5th, 2025. The options feature a ten-year term with a four-year vesting schedule: 25% vesting after one year, followed by monthly installments over 36 months, contingent on continued employment.
Gossamer Bio (NASDAQ:GOSS), a late-stage clinical biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2025. The company, which focuses on developing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present at the Cantor Global Healthcare Conference (September 3rd), Wells Fargo Healthcare Conference (September 4th), and H.C. Wainwright Global Healthcare Conference (September 9th).
The presentations include fireside chats and one-on-one meetings with investors, with events taking place in New York and Boston.
Gossamer Bio (Nasdaq: GOSS), a late-stage clinical biopharmaceutical company, announced the approval of inducement grants to three non-executive employees. The Compensation Committee approved non-qualified stock options to purchase up to 168,750 shares of common stock under the company's 2023 Inducement Plan.
The options have an exercise price of $2.16 per share, matching Gossamer's closing price on August 5th, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Gossamer Bio (NASDAQ: GOSS) reported Q2 2025 financial results and provided updates on its lead drug candidate seralutinib. The company completed enrollment of 390 patients in its Phase 3 PROSERA study for PAH treatment, with topline results expected in February 2026. The study's primary endpoint is change in six-minute walk distance at week 24.
Financial highlights include $212.9 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $11.5 million, with a net loss of $38.3 million ($0.17 per share). The company is also preparing to launch the Phase 3 SERANATA study for PH-ILD in Q4 2025, targeting approximately 480 patients.
Gossamer Bio (NASDAQ: GOSS), a late-stage clinical biopharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 15, 2025. The company, which focuses on developing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will host a conference call and webcast at 4:30 p.m. ET on the same day. Management will discuss financial results and provide a corporate update during the call.
Gossamer Bio (GOSS) has granted stock options to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase up to 258,750 shares at an exercise price of $1.25 per share, matching GOSS's closing price on May 5, 2025. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment. The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).